. "Hepatic processing determines dual activity of alpha-tocopheryl succinate: a novel paradigm for a shift in biological activity due to provitamin-to-vitamin conversion"@en . . . "1024;1027" . "Biochemical and Biophysical Research Communications" . . "523178" . . "Z(AV0Z5052915)" . . . "[29B9D2201E74]" . "Zpracov\u00E1n\u00ED v j\u00E1trech determinuje dvoj\u00ED aktivitu alfa-tokoferyl sukcin\u00E1tu: nov\u00E9 paradigma pro zm\u011Bnu biologick\u00E9 aktivity zp\u016Fsobenou p\u0159eveden\u00EDm provitam\u00EDnu na vitam\u00EDn"@cs . "Massa, H." . "Hepatic processing determines dual activity of alpha-tocopheryl succinate: a novel paradigm for a shift in biological activity due to provitamin-to-vitamin conversion" . "4"^^ . "Redoxn\u011B uml\u010Den\u00E1 analoga vitam\u00EDnu E jako nap\u0159. alfa-tokoferyl sukcin\u00E1t p\u0159edstavuj\u00ED l\u00E1tky se siln\u00FDmi protirakovinn\u00FDmi \u00FA\u010Dinky spojen\u00FDmi s jejich potenci\u00E1ln\u00ED sekund\u00E1rn\u00ED biologickou aktivitou. Ov\u011B\u0159ovali jsme hypot\u00E9zu, \u017Ee zpracov\u00E1n\u00ED t\u011Bchto l\u00E1tek v j\u00E1trech determinuje jejich sekund\u00E1rn\u00ED \u00FA\u010Dinku. My\u0161\u00EDm jsme opakovan\u011B injikovali alfa-tokoferyl sukcin\u00E1t a v jejich syst\u00E9mov\u00E9m ob\u011Bhu a krvi jatern\u00ED \u017E\u00EDly jsme sledovali alfa-tokoferyl sukcin\u00E1t a produkt jeho hydrol\u00FDzy vitam\u00EDn E (alfa-tokoferol). Zat\u00EDmco hladiny alfa-tokoferolu se ve srovn\u00E1n\u00ED s kontrolami zdvojn\u00E1sobily a alfa-tokoferyl sukcin\u00E1t se hromadil v syst\u00E9mov\u00E9m ob\u011Bhu, v krvi odv\u00E1d\u011Bn\u00E9 z jater nebyl nalezen \u017E\u00E1dn\u00FD alfa-tokoferyl sukcin\u00E1t. Zpracov\u00E1n\u00ED l\u00E1tek jako alfa-tokoferyl sukcin\u00E1t j\u00E1try jim tedy zaji\u0161\u0165uje sekund\u00E1rn\u00ED, antioxida\u010Dn\u00ED/protiz\u00E1n\u011Btlivou aktivitu t\u00EDm, \u017Ee je p\u0159ev\u00E1d\u00ED na redoxn\u011B aktivn\u00ED alfa-tokoferol. N\u00E1\u0161 poznatek tedy raz\u00ED nov\u00E9, obecn\u00E9 paradigma, \u017Ee l\u00E1tka m\u016F\u017Ee b\u00FDt p\u0159evedena j\u00E1try na produkt s odli\u0161nou u\u017Eite\u010Dnou biologickou aktivitou."@cs . . "2"^^ . "327" . "Hepatic processing determines dual activity of alpha-tocopheryl succinate: a novel paradigm for a shift in biological activity due to provitamin-to-vitamin conversion"@en . . "Neu\u017Eil, Ji\u0159\u00ED" . "Redox-silent vitamin E analogues, represented by alpha-tocopheryl succinate, are potent anti-cancer drugs with potential secondary bioactivity. We verified the hypothesis that hepatic processing of these agents determines the secondary effect. Mice were repeatedly injected with alpha-tocopheryl succinate, and their systemic and hepatic vein blood was assessed for alpha-tocopheryl succinate and its hydrolysis product, vitamin E (alpha-tocopherol). While levels of alpha-tocopherol doubled compared to control mice and alpha-tocopheryl succinate accumulated in the systemic blood, no alpha-tocopheryl succinate was detected in blood draining the liver. Hepatic processing thus endows compounds like alpha-tocopheryl succinate with a secondary, anti-oxidant/anti-inflammatory activity due to converting it to the redox-active alpha-tocopherol. Our finding epitomises a novel, general paradigm that a drug can be converted in the liver into a product that has a different beneficial bioactivity."@en . . "Zpracov\u00E1n\u00ED v j\u00E1trech determinuje dvoj\u00ED aktivitu alfa-tokoferyl sukcin\u00E1tu: nov\u00E9 paradigma pro zm\u011Bnu biologick\u00E9 aktivity zp\u016Fsobenou p\u0159eveden\u00EDm provitam\u00EDnu na vitam\u00EDn"@cs . . . "Hepatic processing determines dual activity of alpha-tocopheryl succinate: a novel paradigm for a shift in biological activity due to provitamin-to-vitamin conversion" . "1"^^ . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "RIV/68378050:_____/05:00001255!RIV06-AV0-68378050" . "vitamin E; alpha-tocopheryl succinate; hepatic processing"@en . . . "4" . "Redox-silent vitamin E analogues, represented by alpha-tocopheryl succinate, are potent anti-cancer drugs with potential secondary bioactivity. We verified the hypothesis that hepatic processing of these agents determines the secondary effect. Mice were repeatedly injected with alpha-tocopheryl succinate, and their systemic and hepatic vein blood was assessed for alpha-tocopheryl succinate and its hydrolysis product, vitamin E (alpha-tocopherol). While levels of alpha-tocopherol doubled compared to control mice and alpha-tocopheryl succinate accumulated in the systemic blood, no alpha-tocopheryl succinate was detected in blood draining the liver. Hepatic processing thus endows compounds like alpha-tocopheryl succinate with a secondary, anti-oxidant/anti-inflammatory activity due to converting it to the redox-active alpha-tocopherol. Our finding epitomises a novel, general paradigm that a drug can be converted in the liver into a product that has a different beneficial bioactivity." . . "RIV/68378050:_____/05:00001255" . "0006-291X" .